|Bid||133.23 x 100|
|Ask||134.10 x 400|
|Day's Range||139.67 - 141.23|
|52 Week Range||118.89 - 146.87|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.04%|
How Is Vertex Pharmaceuticals Positioned after 4Q17? In 4Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of $365 million, which reflected ~32% growth on a year-over-year (or YoY) basis and 9% growth on a quarter-over-quarter (or QoQ) basis. In fiscal 2017, Orkambi generated revenues of $1.3 billion, a ~35% increase on a YoY basis.
Warren Buffett is arguably the most famous investor of our time — likely all-time. Some others, like Carl Icahn, Jim Chanos and George Soros are well-known and for good reason. Humble about himself and with his wallet, Buffett has pretty sound (and simple) advice for retail investors, specifically when it comes to Vanguard funds.
According to Intuitive Surgical’s (ISRG) preliminary 4Q17 and 2017 results posted by the company on January 10, 2018, it expects to post da Vinci procedure growth of 17% in 4Q17 and 16% for fiscal 2017 on a YoY (year-over-year) basis. About 877,000 procedures are estimated to be performed with da Vinci surgical systems around the world in fiscal 2017. The US general surgery and global urologic procedure growths continue to be the major drivers behind the da Vinci procedure growth.
While marijuana legalization for recreational use is just gaining attention around the world, it’s also facing strong opposition. According to some, legalizing marijuana will just increase substance abuse. Some groups are concerned that legalizing marijuana would make it even easier for young people to access the drug.
In the previous part of this series, we discussed Constellation Brands’ (STZ) investment in the marijuana industry. Given that legislative approval is the strongest driving factor behind the boost in the marijuana industry, companies have rushed to capitalize on the wave. Below, we discuss some of the business opportunities that could develop as a result of marijuana legalization.
In the previous part of this series, we analyzed the performance of the US market (SPX-INDEX) (SPY). Although the global equity market had the best start to a new year that it has seen since 1988, investors should be cautious, according to Pimco. The MSCI All-Country World Index (ACWI), which tracks the performance of the global market, rose 4.8% between January 2, 2018, and January 18, 2018.
Investing doesn't need to be complicated or expensive. Build a dirt-cheap portfolio that can last a lifetime with just one stock ETF and one bond ETF.
What Could Drive Bristol-Myers Squibb in 2018? In December 2017, the U.S. FDA (Food and Drug Administration) approved Bristol-Myers Squibb’s (BMY) Opdivo as adjuvant therapy for individuals with melanoma with the involvement of lymph nodes or metastatic disease who have undergone complete resection. The objective of the adjuvant therapy is to reduce the risk of recurrence after surgical removal of the tumor.
How Is Amgen Positioned for 2018? In January 2018, the FDA approved Amgen’s (AMGN) supplemental Biologics License Application (or sBLA) for Xgeva. Xgeva is used for the prevention of skeletal-related events in individuals with bone metastasis from solid tumors.